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Anne U. Jackson,3 Ying Wu,1 Mete Civelek,4,5 Aldons J. Lusis,4,6,7 Kyle J. Gaulton,1,8
Praveen Sethupathy,1 Antti J. Kangas,9 Pasi Soininen,9,10 Mika Ala-Korpela,9,10,11,12 Johanna Kuusisto,13
Francis S. Collins,14 Markku Laakso,13 Michael Boehnke,3 and Karen L. Mohlke1,*
Genome-wide association studies (GWASs) have identified more than 150 loci associated with blood lipid and cholesterol levels; how-
ever, the functional and molecular mechanisms for many associations are unknown. We examined the functional regulatory effects of
candidate variants at the GALNT2 locus associated with high-density lipoprotein cholesterol (HDL-C). Fine-mapping and conditional
analyses in the METSIM study identified a single locus harboring 25 noncoding variants (r2 > 0.7 with the lead GWAS variants) strongly
associated with total cholesterol in medium-sized HDL (e.g., rs17315646, p ¼ 3.53 1012). We used luciferase reporter assays in HepG2
cells to test all 25 variants for allelic differences in regulatory enhancer activity. rs2281721 showed allelic differences in transcriptional
activity (75-fold [T] versus 27-fold [C] more than the empty-vector control), as did a separate 780-bp segment containing rs4846913,
rs2144300, and rs6143660 (49-fold [AT– haplotype] versus 16-fold [CCþ haplotype] more). Using electrophoretic mobility shift assays,
we observed differential CEBPB binding to rs4846913, andwe confirmed this binding in a native chromatin context by performing chro-
matin-immunoprecipitation (ChIP) assays in HepG2 and Huh-7 cell lines of differing genotypes. Additionally, sequence reads in HepG2
DNase-I-hypersensitivity and CEBPB ChIP-seq signals spanning rs4846913 showed significant allelic imbalance. Allelic-expression-
imbalance assays performed with RNA from primary human hepatocyte samples and expression-quantitative-trait-locus (eQTL) data
in human subcutaneous adipose tissue samples confirmed that alleles associated with increased HDL-C are associated with a modest in-
crease in GALNT2 expression. Together, these data suggest that at least rs4846913 and rs2281721 play key roles in influencing GALNT2
expression at this HDL-C locus.Introduction
Genome-wide association studies (GWASs) have identified
more than 150 loci associated with blood lipid and choles-
terol levels.1–5 One of the first novel GWAS signals for
high-density lipoprotein cholesterol (HDL-C) levels in
Europeans was reported for variants rs2144300 and
rs4846914, located within intron 1 of GALNT26,7(MIM:
602274). These two lead GWAS variants are in perfect link-
age disequilibrium (LD; r2 ¼ 1). The association signal for
rs4846914 has been replicated (n ¼ 187,000 individuals,
p ¼ 4 3 1041) in subsequent studies with larger sample
sizes2,4 and in Japanese and Mexican populations.8,9
HDL-C-associated variant rs4846914 is also associated
(n ¼ 178,000, p¼ 73 1031) with triglycerides4 and nomi-
nally associated (n¼ 2,744–3,481, p< 0.05) with largeHDL
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to HDL-C.10 The alleles associated with increased HDL-C
are also nominally associated (n ¼ 84,068, p ¼ 0.04) with
decreased risk of coronary artery disease.4
According to 1000 Genomes phase 1 version 3 European
(EUR) data,11 24 variants exhibit strong LD (r2 > 0.7) with
the lead GALNT2 HDL-C-associated SNP, rs4846914, and
all 25 variants are noncoding. According to available chro-
matin data from the ENCODE Project12 and Human Epige-
nome Atlas,13 these variants overlap many candidate regu-
latory regions. Therefore,wehypothesized that oneormore
of these variants regulate gene expression. Many variants
identified through GWASs are located within noncoding
or intergenic regions,14,15 and variants at theGALNT2 locus
might also alter regulatory elements.
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reasonable positional candidate within the HDL-C associa-
tion signal. GALNT2 is an enzyme that transfers an N-ace-
tylgalactosamine to serine or threonine residues in target
proteins in the initial step of O-linked glycosylation.16
GALNT2 is expressed inmany tissues, including liver, heart,
lung, muscle, pancreas, ovary, and colon.17–19 GALNT2
might influence HDL-C levels by catalyzing O-glycosyla-
tion on target proteins that play a role in lipid metabolism.
In vitro,GALNT2has been shown toO-glycosylate lecithin-
cholesterol acyltransferase (LCAT), phospholipid transfer
protein (PLTP), and angiopoietin-like protein3 (ANGPTL3),
and O-glycosylation of ANGPTL3 was shown to inhibit
activation of this protein.20 Individuals heterozygous for
a GALNT2 missense variant (c.941A>C [p.Asp314Ala])
shown to decrease GALNT2 function in vitro exhibit
decreased glycosylation of apoC-III and high (>95th
percentile for age and gender) plasma HDL levels.21 In
mice, liver-specific Galnt2 overexpression and knockdown
have been shown to decrease and increase HDL-C levels,
respectively.2
We aimed to identify the functional regulatory variant(s)
responsible for the GALNT2 HDL-C GWAS signal by fine
mapping the association with lipoprotein traits in the
METSIM (Metabolic Syndrome in Men) study22 and by
examining a comprehensive set of candidate variants for
evidence of allelic differences in enhancer function. We
identified a single signal driven by at least two regulatory
variants, rs4846913 and rs2281721, that exhibited binding
of transcription factors and allelic differences in enhancer
activity, as well as additional variants thatmight contribute
to enhancer function. In human hepatocyte and subcu-
taneous adipose tissue samples, we observed an association
between this GWAS signal and GALNT2 expression.
Together, these data show a consistent direction of regula-
tory effect in which increased expression of GALNT2 is
implicated in increased HDL-C.Material and Methods
Defining the Candidate Set of Variants
We used the 1000 Genomes Project Phase 1 version 3 EUR data-
set,11 including 24 variants in strong LD (r2 > 0.7) with the lead
HDL-C GWAS SNP rs4846914, to calculate LD. We used ENCODE
data12 available through the UCSC Genome Browser to determine
which of the 25 total variants overlapped open-chromatin peaks
and chromatin-immunoprecipitation-sequencing (ChIP-seq)
peaks of histone modifications H3K4me1, H3K4me2, H3K4me3,
H3K9ac, and H3K27ac and transcription factors in liver cell types
(HepG2 cells, Huh-7 cells, and primary human hepatocytes) and
ChromHMM chromatin states23 in multiple cell types. We used
the Human Epigenome Atlas13 to determine overlap with peaks
of H3K4me1 and H3K9ac in primary adult liver and with
ChromHMM chromatin states in multiple cell types and tissues.Genotyping and Imputation
We used the Illumina HumanOmniExpress and HumanCoreEx-
ome24 Beadchips to genotype 10,134 Finnish men from the MET-802 The American Journal of Human Genetics 97, 801–815, DecembSIM study.22 Sample-level and SNP-level quality control included
detecting sample contamination,25 confirming sex and relation-
ships, andusingprincipal-component analysis to detect population
outliers. After we filtered SNPs to retain those with a call rate of
>95% and Hardy-Weinberg Equilibrium p > 106, we successfully
analyzed 10,082 individuals and 681,803 SNPs. TheMETSIM study
was approved by the ethics committee of the University of Kuopio
and Kuopio University Hospital, and informed consent was ob-
tained from all study participants. To impute ungenotyped SNPs,
weused a panel of 5,474 referencehaplotypes derived fromgenome
sequences of 2,737 central-northern European individuals
sequenced as part of the Genetics of Type 2 Diabetes study (C.F., J.
Flannick,K.J.G.,H.Kang, and theGoT2DConsortium,unpublished
data). The minimum MaCH imputation quality score for the
imputed variants was R2 ¼ 0.971. We used a two-step imputation
strategy wherein individuals were pre-phased with ShapeIT version
2 before imputation usingMinimac.26,27We also used these data to
verify LD proxies for allelic-expression-imbalance (AEI) assays.Fine-Mapping and Conditional Analyses
We analyzed 72 measures of lipid and lipoprotein particle-serum
concentration obtained via nuclear-magnetic-resonance (NMR)me-
tabolomics (65 traits) or enzymatic assays (7 traits) in up to 10,079
Finnishmen. The NMRplatformhas been described previously.28,29
The methodology for measuring lipoprotein subclasses has been
described previously,30 and subclasses are defined in Table S1. Trait
values with skewed distributions were log transformed, and all traits
were Winsorized at 5 SDs from the mean. After adjustment for age,
squared age, smoking status, and lipid-lowering-medication status,
we transformed residuals to a standard normal. We tested for asso-
ciation between normalized residuals and SNPs with a minor allele
frequency (MAF) > 0.0005 (minor allele count > 10) by assuming
an additive genetic model and using a linear mixed model with
an empirical kinship matrix to account for relatedness, as imple-
mented in EMMAX.31 We repeated the analysis while excluding
individuals on lipid-lowering medication (2,844 participants), indi-
viduals with type 1 or 2 diabetes (1,420 participants), or both (3,560
participants) to assess sensitivity to these exclusions, and in each
instance we obtained qualitatively similar results. To identify any
additional independent signals in the region, we performed a con-
ditional analysis by using the rs17315646 allele count as an addi-
tional covariate in the model. LocusZoom32 plots were generated
to include 2,079 variants in a 350-kb region surrounding the lead
variant rs17315646 and spanning GALNT2.Cell Culture
Human HepG2 hepatocellular carcinoma cells (ATCC, HB-8065)
were grown in Eagle’s minimum essential medium (MEM) alpha
supplemented with 10% fetal bovine serum (FBS) and 1 mM so-
dium pyruvate at 37C and 5%CO2. HumanHuh-7 hepatocellular
carcinoma cell lines (JCRB0403, Japanese Collection of Research
Bioresources Cell Bank, National Institute of Biomedical Innova-
tion) were grown in DMEM supplemented with 10% FBS, 1 mM
sodium pyruvate, 13 MEM non-essential amino acids, and
2 mM L-glutamine. HepG2 and Huh-7 cells were seeded into
24-well plates (100,000 cells per well) 1 day prior to transfection
experiments.Transcriptional Reporter Assays
To test candidate variants and haplotypes for allele-specific effects
on transcriptional activity, we amplified segments of 109–262 bper 3, 2015
(for single variants) and 349–780 bp (for multiple variants) from
DNA of individuals homozygous for each allele or haplotype.
Segment size was chosen to include the ~147 nucleotides of
DNA spanning one nucleosome. However, because of the prox-
imity of other candidate variants, larger segments of 349–780 bp
were designed to include multiple variants. Primer sequences are
listed in Table S2. Amplicons were cloned into the KpnI and
XhoI restriction sites of the firefly luciferase transcriptional re-
porter vector pGL4.23 in both forward and reverse orientations
with respect to the minimal promoter (Promega). Three to seven
independent plasmids for each allele or haplotype were isolated
and confirmed by sequencing. When additional variants were
identified, we selected clones for which the alleles matched at
these variants. For simplicity of presentation, Figures 3 and S2
do not show the differing alleles of rs1555290; these data are pro-
vided in Figures 4 and S5. We then transfected each purified clone
into HepG2 or Huh-7 cells in duplicate (720 ng in each well) by us-
ing FuGENE 6 (Promega) and Opti-MEM (Life Technologies). To
control for transfection efficiency, we co-transfected a phRL-TK Re-
nilla luciferase reporter vector (80 ng in each well) into cells. For
empty-vector controls, two independent preparations of empty
vector were each transfected into HepG2 or Huh-7 cells in dupli-
cate. After 48 hr, cell-lysate luciferase activity was measured with
the Dual-Luciferase Reporter Assay System (Promega), normalized,
and compared to readings for empty-vector controls. These con-
trol readings were very similar for the two independent prepara-
tions. We performed two-tailed t tests to compare the luciferase ac-
tivities between variant alleles. For comparisons of multiple
haplotypes, we performed ANOVA and Tukey’s post hoc tests by
using JMP 10.0.1 software (SAS Institute). We also assessed the
transcriptional activity of the 780-bp segment by cloning the
haplotype into the promoterless pGL4.10 firefly luciferase reporter
vector (Promega). To examine individual variant effects within the
780-bp segment, we altered alleles by using the QuikChange Site-
Directed Mutagenesis Kit (Agilent Technologies) and confirmed
them by sequencing.
Electrophoretic Mobility Shift Assays
Complementary DNA oligonucleotides (17–19 bp) centered on
variant alleles (Table S2) were synthesized by Integrated DNATech-
nologies. The rs6143660 insertion allele consisted of 39-bp comple-
mentary oligonucleotides containing the 21-bp insertion (9 bp
flanking each side of the insertion), and the rs6143660 deletion
allele consisted of 18-bp complementary oligonucleotides (9 bp
flanking each side of the deleted sequence). Labeled oligonucleo-
tides included biotin on the 50 end. We performed assays as
previously described33 by using 3.5–6 mg of HepG2 nuclear lysate
and30- to300-fold excessunlabeledprobe. For supershift reactions,
4–8 mg CEBPB antibody (sc-150X), USF1 antibody (sc-229X), and
FOXO3 antibody (sc-34895X), all from Santa Cruz Biotechnology,
were incubated with binding buffer, poly(dI$dC), and HepG2 nu-
clear lysate for 20 min at room temperature before the addition of
labeled DNA probes and incubation. Additional control antibodies
(4–6 mg, all fromSantaCruz Biotechnology) were chosen on the ba-
sis of transcription-factorbindingmotifs, ENCODEChIP-seqpeaks,
expression of transcription factors in liver, or plausible roles of the
factors in cholesterol metabolism. These included antibodies to
ARNT (sc-271801X), SF1 (sc-10976X), HNF4A (sc-6556X), RXRA
(sc-553X), CEBPA (sc-61X), CEBPB (sc-150X), NR1H3 (sc-1202X),
andMAX (sc-765X). Reactions were loaded into a 6%DNA retarda-
tion gel (Life Technologies), subjected to electrophoresis, trans-
ferred to Biodyne B nylon membranes (Life Technologies), andThe AmericanUV crosslinked. Wash and detection steps were performed accord-
ing to instructions in the Chemiluminescent Nucleic Acid Detec-
tion Module (Life Technologies). Experiments involving electro-
phoretic mobility shift assays (EMSAs) were repeated on 2–7
separate days, and all had consistent results.
To predict transcription-factor binding sites, we searched data-
bases for transcription-factor binding-site motifs in 17- to 21-bp
genomic sequences containing each allele of candidate variants.
For JASPAR,34 we searched all available matrix models with a rela-
tive profile-score threshold of 80%. We also searched positional-
weight matrices (PWMs) from vertebrates in TRANSFAC by using
default parameters in the TRANSFAC Professional’s Match tool
and by using PWM-SCAN.35ChIP Assays
We used a TaqMan SNP Genotyping Assay (Life Technologies) to
genotype HepG2 and Huh-7 cells at rs4846913. Cells were cross-
linked with 1% formaldehyde, and glycine was added to stop fix-
ation. Fixed cells were resuspended in SDS lysis buffer (1% SDS,
10 mM EDTA, and 50 mMTris [pH 8.1]), diluted with immunopre-
cipitation (IP) buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM
EDTA, 16.7 mM Tris [pH 8.1], and 167 mM NaCl), and sonicated
on ice with a Branson sonifier for the generation of 100- to
500-bp DNA fragments. Each CEBPB IP or immunoglobulin G
(IgG) reaction used two to three million cells. After preclearing
with Protein A Agarose beads (sc-2001, Santa Cruz Biotechnology),
10 mg of CEBPB antibody (sc-150X, Santa Cruz Biotechnology) or
10 mg of normal rabbit IgG (sc-2027, Santa Cruz Biotechnology)
was added to HepG2 and Huh-7 cell lysates and incubated over-
night. Protein A Agarose beads were then added for 3 hr and
washed separately with low-salt buffer, high-salt buffer, LiCl
buffer, 10 mM Tris-EDTA, and elution buffer (1% SDS and 0.1 M
NaHCO3). The crosslinks were then reversed by the addition of
5 M NaCl and overnight incubation. Samples were incubated
with 20 ml 1M Tris, 10 ml 0.5 M EDTA, and 0.03 mg proteinase K.
DNA was purified by phenol-chloroform extraction and ethanol
precipitation. For qPCR, a 120-bp region spanning rs4846913
was amplified with FAST SYBR Green Master Mix (Life Technolo-
gies). qPCRwas performed in triplicate and quantifiedwith respect
to a standard curve generated from sonicated HepG2 DNA stan-
dards. The mean quantities of CEBPB IP and IgG control sample
were normalized to input HepG2 or Huh-7 DNA. CEBPB and IgG
ChIP experiments with HepG2 and Huh-7 cells were each per-
formed twice and had similar results. We used two-tailed t tests
to compare CEBPB enrichment of the rs4846913 region in
HepG2 and Huh-7 cells.
We performed USF1 ChIP assays similarly, except that we used a
Diagenode Bioruptor Standard sonicator. We used 10 mg of USF1
antibody (sc-229X, Santa Cruz Biotechnology) or 10 mg IgG
(sc-2027, Santa Cruz Biotechnology) and purified DNA with the
QIAquick PCR Purification Kit (QIAGEN) to amplify and quantify
a 164-bp region spanning rs2281721.We performed USF1 and IgG
ChIP experiments with HepG2 and Huh-7 cells twice each, and
they had similar results.Allelic-Imbalance Analysis of Sequence Reads from
CEBPB ChIP-Seq and DNase-Seq
Sequence reads from HepG2 for DNase-I-hypersensitivity-site
sequencing (DNase-seq) and CEBPb ChIP-seq experiments gener-
ated by the ENCODE Consortium12 were aligned to UCSC
Genome Browser build hg19 with AA-ALIGNER.36 In brief, HepG2Journal of Human Genetics 97, 801–815, December 3, 2015 803
genotypes were obtained from the Illumina Human-1M-Duo Bead-
Chip array genotyped at HusdonAlpha Institute of Biotechnology,
and imputation was performed with the 1000 Genomes Phase 1
EUR reference panel.11 Using this data, we verified that HepG2 is
diploid in the chromosome 1 region containing GALNT2, and
we created a personalized HepG2 reference genome containing
non-reference alleles for sites at which HepG2 is homozygous
for the non-reference allele. We aligned sequence reads to the
personalized genome by using HepG2 heterozygous sites identified
by imputationandGSNAP37with the followingparameters: -m1, -k
11, –basesize ¼ 11, -sampling ¼ 1, -terminal-threshold ¼ 10, -n
1, -query-unk-mismatch ¼ 1, -genome-unk-mismatch ¼ 1, -trim-
mismatch-score ¼ 0, -t 7, and –A sam. We filtered the alignments
to remove sequences aligned to more than one genomic location,
sequences aligned to regions underrepresented in the reference
sequence (ENCODE blacklisted12 regions), and duplicate reads
that might represent PCR artifacts. We determined the significance
of allelic imbalance at rs4846913 by using an exact binomial test,
based on the number of reads containing the reference allele and
the total number of reads at the heterozygous site. For the HepG2
DNase-seq data and USF1 HepG2 ChIP-seq data, insufficient reads
were available for allelic imbalance analysis at rs2281721.
Preparation of cDNA for GALNT2 mRNA-Expression
and AEI Assays
RNA and DNA were isolated from hepatocyte samples of 50 indi-
viduals as described previously.38 RNA for each sample was treated
with DNase I with the DNA-free Kit (Life Technologies) and added
to a final concentration of 24 ng/ml in an RT-PCR reaction in the
SuperScript III First-Strand Synthesis System (Life Technologies),
which includes both oligo(dT)20 and random hexamer primers.
The synthesized cDNA for each sample was then diluted with di-
ethylpyrocarbonate (DEPC)-treated water for use inmRNA-expres-
sion and AEI assays.
AEI Assays
We used a TaqMan SNP genotyping assay (Life Technologies) to ge-
notype human hepatocyte genomic DNA (gDNA) from ADMET
Technologies for the HDL-C index SNP rs4846914. To quantify
allele-specific expression, we diluted hepatocyte cDNA and gDNA
from36 individualsheterozygous for rs4846914andperformedsub-
sequent qPCR reactions in triplicate. To generate a standard curve,
we mixed gDNAs from samples homozygous for each rs4846914
allele in the following ratios: 95:5, 72.5:27.5, 61.25:38.75, 50:50,
38.75:61.25, 27.5:72.5, and 5:95. We generated a standard curve
by plotting the quantity of one allele against the difference between
the cycle-threshold (Ct) values of the two alleles. For each heterozy-
gous sample,weestimated theexpressionpercentageofonealleleby
using the difference between the mean Ct values of the alleles and
the standard curve.38 We used two-tailed t tests to compare gDNA
and cDNA values and used F-tests to determine equal or unequal
variance between gDNA and cDNA samples.38,39
GALNT2 Hepatocyte mRNA Expression
We measured expression of GALNT2 in 50 human hepatocyte
samples by qPCR with a standard curve and FAST SYBR Green
Master Mix (Life Technologies). We performed triplicate qPCR
reactions including 9 ng of total cDNA in each well, Taqman
Gene Expression Master Mix (Life Technologies), and primer-set
sequences within GALNT2 exons (Table S2). GALNT2 expression
values were normalized to the expression of beta-2-microglobulin804 The American Journal of Human Genetics 97, 801–815, Decemb(B2M [MIM: 109700]), natural-log transformed, and plotted ac-
cording to the rs4846914 genotype (AA, AG, andGG). Using linear
regression and an additive model including sex, ancestry, and age
as covariates, we tested for association between the level of
GALNT2 mRNA and the rs4846914 genotype.
Lookup of Expression Quantitative Trait Loci in
Subcutaneous Adipose Tissue
We looked for evidence of association between the HDL-C GWAS
variant region and gene expression by using preliminary microar-
ray expression data from subcutaneous adipose tissue from the
METSIM study. In brief, we used EPACTS-multi (with EMMAX im-
plemented to account for family relatedness) Affymetrix Human
Genome U219 Array data for 1381 individuals was adjusted for
40 confounding factors,40 inverse-normal transformed, and tested
for association with variants. We analyzed variants within 1Mb of
rs4846914 and identified one probe set for GALNT2 and other
genes located in this region. Subsequent reciprocal conditional
analyses included two variants in each model.
siRNA-Mediated Knockdown of CEBPB
HepG2 cells (80,000 per well) were plated into 24-well collagen-
coated plates and then treated with 50 nM CEBPB Silencer Select
small interfering RNA (siRNA; s2893, Thermo Fisher Scientific)
or Silencer Select Negative Control No. 1 siRNA (4390843, Thermo
Fisher Scientific) with Opti-MEM (Life Technologies) and Dharma-
FECT1 transfection reagent (GE Healthcare Life Sciences) on the
following day. Cells were incubated at 37C with 5% CO2 for
48 hr, and HepG2 medium was changed the day following siRNA
transfection. RNA was harvested with the RNeasy Plus Mini Kit
(QIAGEN), and cDNA was prepared with the SuperScript III First-
Strand Synthesis System (Life Technologies). CEBPB and GALNT2
expression was measured by qPCR with a standard curve. Raw
expression values were normalized to the expression of B2M,
and expression percentages were calculated by comparison to
expression values in HepG2 cells transfected with the negative
control siRNA. Primers for gene expression are listed in Table S2.
We used two-tailed t tests to compare normalized GALNT2 expres-
sion between HepG2 cells treated with CEBPB siRNA and HepG2
cells treated with negative control siRNA.Results
Fine Mapping Shows Evidence of a Single Association
Signal Strongest for Total Cholesterol in Medium HDL
We tested one of the HDL-C-associated lead GWAS vari-
ants, rs2144300 (r2 ¼ 1 with rs4846914), for association
with 72 lipid and cholesterol traits in up to 10,079 Finnish
men from theMETSIM study. The strongest evidence of as-
sociation across all 72 traits was with total cholesterol in
medium HDL (n ¼ 9,810, b ¼ 0.10, p ¼ 5.3 3 1012; Table
S3). Using this trait and variants that were directly geno-
typed or imputed from a reference panel of 2,737 genomes
of central-northern European individuals, we performed
fine-mapping association and conditional analyses.
Among 2,079 total variants in the region spanning 350
kb surrounding the lead variant, the strongest evidence
of association was observed for rs17315646 (n ¼ 9,810,
p ¼ 3.5 3 1012), which is in perfect LD (r2 ¼ 1) wither 3, 2015
Figure 1. Non-coding Variants at
GALNT2 Are Associated with Total Choles-
terol in MediumHDL in theMETSIM Study
The entire initial association signal (upper
panel) was reduced after conditioning on
lead SNP rs17315646 (lower panel). Circles
represent genotyped and imputed DNA
variants and their LD r2 values with
rs17315646 in the METSIM study (2,079
variants are shown). Chromosome coordi-
nates correspond to UCSC Genome
Browser build hg19. The left y axis indi-
cates the log10(p value), the right y axis
indicates the recombination rate (cM/
Mb), and the x axis indicates position on
chromosome 1 (Mb).HDL-C GWAS lead SNPs rs4846914 (n ¼ 9,810, p ¼ 5.3 3
1012) and rs2144300 (n ¼ 9,810, p ¼ 5.33 1012). Condi-
tioning on rs17315646 attenuated the 13.7-kb association
signal (all p> 0.01; Figure 1 and Table S4). The new lead var-
iants after conditional analysis (pcond ~ 10
4–106) showed
weak initial evidence of association (p ~ 102–104) and
have a MAF < 0.04 (Table S4). These data provide evidence
that common variants in strong LD with rs4846914 and
rs17315646 are most likely responsible for the HDL-C asso-
ciation signal. All 25 candidate variants (r2 > 0.7 with
HDL-C GWAS lead variant rs4846914) are located within
intron 1 of GALNT2. These variants all exhibited strong
evidence of association with total cholesterol in medium
HDL (p% 1.45 3 109; Table S4).
Open-Chromatin, Histone-Modification, and
Transcription-Factor Marks Indicate Potential
Regulatory Elements Overlapping the GALNT2
Association Signal
We hypothesized that one or more of the 25 HDL-C-associ-
ated non-coding variants affect transcriptional activity. WeThe American Journal of Human Genasked whether regulatory datasets
from the ENCODEProject andHuman
Epigenome Atlas could help us iden-
tify variants that exhibit regulatory ac-
tivity.Wecompared the locationof the
25 candidate variants to regions of
open chromatin depicted by DNase I
hypersensitivity and formaldehyde-
assisted isolation of regulatory ele-
ments (FAIRE); histone-modification
ChIP-seq peaks H3K4me1, H3K4me2,
H3K4me3, H3K9ac, and H3K27ac,
which often mark enhancer or pro-
moter elements; and transcription-
factor ChIP-seq peaks. On the basis of
the liver’s key role in HDL synthesis
and transport, and the enrichment of
lipid GWAS signals in liver,4 we
focused on datasets from human liver
cell lines, primary human hepato-
cytes, and human adult liver cells. All 25 variants overlap
broad patterns of H3K4me1-enriched domains in HepG2
cells (Table S5), and 13 overlap narrower H3K4me1-en-
riched peaks.41 Sixteen variants overlap two or more his-
tone-modification peaks, and six variants (rs4631704,
rs4846913, rs2144300, rs6143660, rs2281721, and
rs11122453) overlap at least one transcription-factor
ChIP-seq peak (Figure 2 and Table S5). Three variants
(rs4846913, rs2144300, and rs6143660) overlap the most
marks of potential regulatory function (at least 22 peaks,
including open-chromatin, histone-modification, and
transcription-factor peaks). According to ChromHMM
data23 from ENCODE12 and the Roadmap Epigenomics
Project,13 all 25 variants are located within predicted
enhancer or transcribed-region chromatin states in
HepG2 cells and primary liver cells (Figure S1). The
regulatory peaks are not specific to liver cells, given that
open-chromatin, histone-modification, and transcription-
factor peaks were also observed in GM12878 lymphoblas-
toid cells, human umbilical-vein endothelial cells
(HUVECs), K562 leukemia cells, CD20þ B cells, CD14þetics 97, 801–815, December 3, 2015 805
Figure 2. HDL-C-Associated Variants Overlap Open Chromatin and HistoneModifications Indicating Potential Regulatory Regions in
GALNT2 Intron 1
A 13.7-kb region includes all 24 variants in strong LD (r2 > 0.7) with the HDL-C-associated index SNP rs4846914 (25 total candidate
variants). Selected Human Epigenome Atlas and ENCODE open-chromatin and histone-modification tracks are shown. Rectangular
bars represent elements containing the variant(s) that were tested in luciferase reporter assays.monocytes, human skeletal-muscle myoblasts (HSMMs),
normal human astrocytes (NHAs), normal human lung fi-
broblasts (NHLFs), and osteoblasts (Figure S1).
All 25 Candidate Regulatory Variants Were Evaluated
for Allelic Differences in Luciferase Activity
Given the limited resolution of open-chromatin peaks and
histone-modification and transcription-factor ChIP-seq
peaks, and the knowledge that these marks do not predict
allelic differences in regulatory activity, we tested all 25
variants in transcriptional reporter assays in luciferase vec-
tors containing a minimal promoter (Figures S2 and S3).
Tested elements contained one to four variants, and three
to seven independent clones for each allele or haplotype in
the element were tested. We considered elements exhibit-
ing >1.5-fold more activity than empty-vector controls
as enhancers. We focused on elements whose enhancer
activity in both forward and reverse orientations was
>1.5-fold higher than that in the luciferase reporter gene
alone, as well as differences (p < 0.05) between the alleles
or haplotypes in both orientations.
rs2281721 Exhibits Allelic Differences in
Transcriptional Activity
Among all the segments tested, a 174-bp DNA segment
containing rs2281721 showed the strongest enhancement
of luciferase activity, and this activity also differed between
the alleles (Figure 3A). In the forward orientation, the DNA
segment containing the rs2281721 Tallele, associated with806 The American Journal of Human Genetics 97, 801–815, Decembincreased HDL-C, showed 75-fold more luciferase activity
than the empty-vector control, whereas the segment con-
taining the rs2281721 C allele showed 27-fold more, and
significant differences were observed between the alleles
(p ¼ 2.4 3 106). In the reverse orientation, the T and C
alleles exhibited 37-fold and 14-fold, respectively, more
luciferase activity than did the control, and there were sig-
nificant differences between the alleles (p ¼ 5.8 3 105).
The rs2281721 T allele also showed stronger enhancer ac-
tivity than did the rs2281721 C allele in both forward
(205-fold versus 59-fold more than in the control) and
reverse (49-fold versus 19-fold more than in the control)
orientations in a second hepatocellular carcinoma cell
line, Huh-7 (both p < 3 3 104; Figure S4A). The segment
and the position of rs2281721 overlaps H3K4me1 peaks
in HepG2 cells and adult liver; H3K4me2, H3K9ac, and
H3K27ac peaks in HepG2 cells; and a USF1 transcription-
factor ChIP-seq peak in HepG2 cells (Figure 2 and Table S5).
A Segment Containing rs4846913, rs2144300, and
rs6143660 Shows Haplotype Differences in
Transcriptional Activity
A780-bpDNA segment containing three variants exhibited
significant haplotype differences in luciferase activity
(Figure 3B). We analyzed two haplotypes of rs4846913,
rs2144300, and rs6143660 (a 21-bp indel): AT (containing
the alleles associated with increased HDL-C) and CCþ (con-
taining the alleles associatedwith decreasedHDL-C). In the
forward orientation, the AT and CCþ haplotypes showeder 3, 2015
Figure 3. Haplotype and Allelic Differ-
ences in Transcriptional Activity at the
GALNT2 Locus
Segments containing each haplotype or
allele were cloned into a pGL4.23 luciferase
reporter vector upstream of the minimal
promoter in both orientations. The vectors
were transfected into HepG2 cells, and
luciferase expression normalized to that
of an empty vector control is shown. Error
bars represent the pairwise SD of three to
six independent clones per allele or haplo-
type (t tests). Abbreviations are as follows:
P, promoter; and luc, luciferase.
(A) Luciferase activity of 174-bp DNA seg-
ments containing rs2281721 alleles.
(B) Luciferase activity of 780-bp DNA
segments of two different haplotypes. The
haplotypes contained three candidate vari-
ants in strong LD: rs4846913, rs2144300,
and 21-bp indel, rs6143660. An additional
variant, rs1555290, was detected in the
segment, as shown in Figures 4 and S5.49-fold and 16-fold, respectively, more luciferase activity
than did the empty-vector control, and significant differ-
ences were observed between the haplotypes (p ¼ 1.8 3
105). In the reverse orientation, the AT and CCþ haplo-
types exhibited 11-fold and 4-fold, respectively, more
luciferase activity than did the empty-vector control,
and significant differences were observed between the
haplotypes (p ¼ 2.0 3 104). The three HDL-C-associated
variants rs4846913, rs2144300, and rs6143660 (a 21-bp
indel) each overlapped R22 open-chromatin, histone-
modification, and transcription-factor peaks (Figure 2
and Table S5).
Haplotype effects on transcriptional activity were
similar in Huh-7 cells. In the forward orientation, haplo-
types AT and CCþ showed 36-fold and 13-fold, respec-
tively, more luciferase activity than did the empty-vector
control; the differences observed between the haplotypes
were significant (p ¼ 1.4 3 105 Figure S4B). In the reverse
orientation, haplotypes AT and CCþ showed 12-fold and
6-fold, respectively, more luciferase activity than did the
empty-vector control (p ¼ 0.08, Figure S4B). The direction
of effect was the same as that of rs2281721; alleles associ-
ated with increased HDL-C showed increased luciferase
activity.
Taken together, our data show consistent haplotype dif-
ferences in luciferase activity for a 780-bp segment consist-
ing of rs4846913, rs2144300, and rs6143600. The results
suggest that these variants are located within an enhancer
element that can affect transcription and that one or
more of themmight have an allelic effect on transcriptional
activity.
The Haplotype Variants Act Together to Regulate
Enhancer Activity
We then created additional haplotypes of the 780-bp
segment by performing site-directed mutagenesis to inves-The Americantigate the variant responsible for allelic differences in tran-
scriptional activity. In addition to including the candidate
variants rs4846913, rs2144300, and rs6143660, the
segment included an additional common variant,
rs1555290, in moderate LD with rs4846914 (D0 ¼ 1, r2 ¼
0.26). We analyzed and tested natural haplotypes of
rs4846913, rs2144300, rs1555290, and rs6143660 (ATA,
CCCþ, and CCAþ), as well as constructed haplotypes
CTA, ACA, CCA, and CCC. These seven haplotypes
were then tested separately in luciferase assays (Figure 4).
ATA, CTA, ACA, and CCA haplotypes showed
44-fold, 38-fold, 31-fold, and 23-fold, respectively, more
luciferase activity than did the empty-vector control, sug-
gesting that both of the first two variants, rs4846913 and
rs2144300, contribute to haplotype differences in tran-
scriptional activity. Specifically, significant differences
were observed between the ATA and ACA haplotypes
(p ¼ 0.04), between the CTA and CCA haplotypes (p ¼
0.04), and between the ATA versus CCA haplotypes
(p ¼ 0.001), supporting a contribution from both
rs4846913 and rs2144300 to haplotype differences in lucif-
erase activity. Compared to the control, the CCAþ, CCC,
and CCCþ haplotypes showed similar 12- to 14-fold in-
creases in luciferase activity (p > 0.05; an intermediate
between the CCA haplotype and the empty vector),
suggesting that rs1555290 and/or rs6143660 might also
contribute to increased transcriptional activity. We
observed similar results in Huh-7 cells: the ATA, ACA,
and CCA haplotypes showed 36-fold, 30-fold, and
27-fold, respectively, more luciferase activity than did
the empty-vector control, and significant differences
were observed between the ATA and CCC haplotypes
(p ¼ 0.0001). Compared to the empty-vector control,
the CCAþ, CCC, and CCCþ haplotypes showed similar
(p > 0.05) 13- to 15-fold increases in luciferase activity
(Figure S5). Taken together, these data suggest a role forJournal of Human Genetics 97, 801–815, December 3, 2015 807
Figure 4. Haplotype Variants Act Together to Increase Tran-
scriptional Activity
Additional haplotypes were created by site-directed mutagenesis
of haplotypes cloned into a pGL4.23 luciferase vector in the for-
ward orientation. All constructs were transfected separately into
HepG2 cells, and this experiment was performed separately from
the experiment presented in Figure 3. Luciferase activity was
measured and normalized to that of an empty vector control. Error
bars represent the pairwise SD of three to four independent clones
per haplotype (ANOVA and Tukey’s post hoc tests). Abbreviations
are as follows: P, promoter; and luc, luciferase.at least two variants, rs4846913 and rs2144300, in haplo-
type differences in enhancer activity.
Because the SNPs in the 780-bp segment overlap
H3K1me1 and H3K4me2 peaks, which are frequently pre-
sent in enhancer regions, as well as a H3K4me3 peak,
which is often found at promoters, we also evaluated the
haplotypes in a promoterless vector (Figure S6). In the for-
ward orientation, haplotypes ATA, CCAþ, and CCCþ
showed 44-fold, 27-fold, 16-fold, respectively, more lucif-
erase activity than did the empty-vector control, and sig-
nificant differences were observed between all haplotype
comparisons (p< 0.001). In the reverse orientation, haplo-
types ATA, CCAþ, and CCCþ exhibited 12-fold, 9-fold,
and 5-fold, respectively, more luciferase activity than did
the empty-vector control, and significant differences
were observed between all the haplotype comparisons
(p < 0.04).
We subsequently analyzed the four variants individually
in 100- to 200-bpDNA segments.Of the four variants tested
individually, only the element containing rs2144300 ex-
hibited enhanced luciferase activity (average 6.5-fold
more than in the empty-vector control). Almost none
of these segments showed allelic differences (p > 0.1;
Figure S7), but rs4846913 did show allelic differences in
only the forward orientation (p¼ 0.03). These data suggest
that the larger segment is necessary for observing allelic dif-
ferences in enhancer activity in this assay.
USF1 Binds to rs2281721
To investigate whether transcription factors bind differen-
tially to rs2281721, rs4846913, rs2144300, rs1555290, and
rs6143660, we performed EMSAs with HepG2 nuclear
lysate. The rs2281721 C probe showed stronger protein
binding than the rs2281721 T probe (lane 2 versus 7, ar-
row, Figure 5). The addition of 40-fold excess unlabeled
rs2281721 C probe competed away the signal more effec-
tively than did unlabeled rs2281721 T probe (lane 3 versus
4). rs2281721 overlaps a USF1 ChIP-seq peak from808 The American Journal of Human Genetics 97, 801–815, DecembENCODE data in HepG2 cells, as well as a predicted USF1
motif. In EMSAs, the addition of a USF1 antibody resulted
in a disruption of the band observed with the C allele
(lane 5). As negative controls, we tested ARNT and SF1 an-
tibodies; we did not observe disruption of the rs2281721
C allele band (Figure S8). These data provide evidence sup-
porting USF1 binding to the C allele of rs2281721.
To validate the USF1 binding in a native chromatin
context, we performed ChIP assays in both HepG2
(rs2281721 genotype T/C) and Huh-7 (rs2281721 geno-
type C/C) cells. The ChIP assays provided evidence sup-
porting USF1 binding to a 164-bp DNA region spanning
rs2281721; however, this binding was not allele specific
(Figure 5B).
CEBPB Binds Differentially to the Alleles of rs4846913
We also observed more protein binding to the A allele
than to the C allele of rs4846913 (lane 2 versus 7, arrow,
Figures 6A and S9). We observed a greater decrease in
band intensity upon addition of 63-fold excess unlabeled
rs4846913 A probe than upon addition of 63-fold excess
unlabeled rs4846913 C probe, suggesting that competi-
tion of the lane 2 band with unlabeled rs4846913 A
probe is more effective than competition with the unla-
beled rs4846913 C probe (lane 3 versus 4). rs4846913
overlaps CEBPB ChIP-seq peaks from ENCODE data in
HepG2 cells and a predicted CEBPB binding motif. Incu-
bation of the EMSA reactions with a CEBPB antibody
generated a strong supershift band for the A allele and
a detectable supershift band for the C allele (lane 5 versus
10, Figure 6A). As negative controls, we tested HNF4A or
RXRA antibodies; we did not observe evidence of super-
shifts (Figure S8).
To validate the differential CEBPB binding in a native
chromatin context, we performed ChIP assays in both
HepG2 (rs4846913 genotype A/C) and Huh-7 (rs4846913
genotype C/C) cells. A 120-bp region of DNA containing
rs4846913 showed 31-fold more CEBPB binding in
HepG2 cells than in Huh-7 cells (p ¼ 0.006; Figure 6B).
These results are consistent with the EMSA result of
increased CEBPB binding to rs4846913 A.
The CEBPB ChIP-seq signal at rs4846913 was sufficiently
strong to permit an analysis of allelic imbalance reflecting
in vivo CEBPB binding.We re-aligned HepG2 CEBPB ChIP-
seq reads and HepG2 DNase-seq reads by using an allele-
aware approach to avoid reference-allele bias (see Material
and Methods). Among CEBPB reads spanning rs4846913,
57 of 78 (73%) contained the rs4846913 A allele (binomial
p ¼ 5.6 3 105; Figure 6C). Among DNase-seq reads span-
ning rs4846913, 31 of 83 (37%) contained the rs4846913 A
allele (binomial p ¼ 0.03; Figure 6C), suggesting that
CEBPB might help protect the DNA sequence containing
the A allele from being accessible to the DNase I enzyme.
Taken together, the EMSA, ChIP, and allelic imbalance in
ChIP-seq and DNase-seq reads all show consistent evi-
dence suggesting stronger CEBPB binding to the A allele
of rs4846913.er 3, 2015
Figure 5. The rs2281721 C Allele Shows
Binding to USF1
(A) EMSAs with biotin-labeled probes con-
taining either the Tor C allele of rs2281721
and incubated with 5 mg HepG2 nuclear
lysate. The arrow indicates an allele-spe-
cific band (lanes 2 and 7), and the asterisk
indicates the C-allele-specific band that
was disrupted upon incubation with USF1
antibody (lane 5). For competition reac-
tions, 40-fold excess unlabeled probe was
added.
(B) ChIP experiments were performed in
HepG2 cells (T/C at rs2281721) and Huh-
7 cells (C/C at rs2281721) with USF1 anti-
body or rabbit IgG control, and a 164-bp
DNA region containing rs2281721 was
amplified via qPCR and quantified with a
standard curve. Results are shown as percentages of input DNA. Error bars represent the SEM of two independent USF1 and IgG ChIP
experiments each in HepG2 and Huh-7 cells.rs2144300, rs1555290, and rs6143660 Also Show
Suggestive Evidence of Protein Binding
EMSAs using HepG2 nuclear lysate for the other variants in
the four-variant haplotype (rs2144300, rs1555290, and
rs6143660) showed suggestive evidence of differential
allelic protein binding (Figures S10–S12). The rs1555290
C probe showed a reproducible band (arrow, Figure S10),
and the addition of 30-fold excess unlabeled rs1555290 C
probe competed away the signal (lane 7) more effectively
than did the addition of 30-fold excess unlabeled
rs1555290 A probe (lane 8). The rs6143660 deletion allele
showedmultiple protein-binding bands (lane 2, Figure S11)
that were altered by incubation with FOXO3 antibody
(Figure S13), although it is challenging to interpret results
when using EMSA probes of different sequence lengths to
compare the 21-bp-insertion and 21-bp-deletion alleles.
However, we did not observe any disruption of the band
corresponding to the rs6143660 deletion allele when we
tested additional antibodies CEBPA, CEBPB, HR1H3,
MAX, and RXRA (Figure S13). A weak, reproducible,
allele-specific band for rs2144300 C was observed, but it
was not fully competed away with excess unlabeled
rs2144300 C probe (Figure S12). Overall, these EMSA
data suggest that these other three variants in the haplo-
type might exhibit differential transcription-factor
binding.
Variants Associated with GALNT2 Expression
On the basis of the location of the HDL-C-associated vari-
ants within GALNT2 intron 1, we hypothesized that these
variants might be acting in cis to regulate GALNT2 expres-
sion. We assessed GALNT2 expression stratified by geno-
type of rs4846914 (r2 ¼ 1 with rs4846913) in 50 primary
human hepatocyte samples, and we observed a trend to-
ward association between genotype and GALNT2 expres-
sion (p ¼ 0.08; Figure S14). To increase the sensitivity by
removing the sample-specific contribution of environ-
mental factors, we performed AEI assays in 36 human
hepatocyte samples heterozygous for rs4846914. Of 142
variants in r2 > 0.2 with rs4846914 in METSIM, none areThe Americantranscribed, so we used qPCR to measure relative allelic
cDNA levels from GALNT2 pre-mRNA at rs4846914. Previ-
ous studies have similarly used intronic SNPs in unspliced
RNA to measure allelic expression.42,43 The rs4846914
A allele, which is associated with increased HDL-C, showed
higher GALNT2 cDNA expression (p ¼ 5.4 3 107;
Figure 7A). When normalized to the allelic difference de-
tected in heterozygous genomic DNA, the A allele of
rs4846914 showed a 7.4% increase in expression. Finally,
we examined rs4846914 in preliminary expression-quanti-
tative-trait-locus (eQTL) data from subcutaneous adipose
tissue from 1,381 individuals in the METSIM study (M.C.
and Y.W., unpublished data) and observed consistent asso-
ciation between the rs4846914 A allele and increased
expression of GALNT2 (p ¼ 2.2 3 1014; Figure 7B),
but not expression of 16 other potential target genes
(p > 0.05/17 ¼ 0.003 on the basis of 17 tests; Figure S15
and Table S6). Conditioning on the lead eQTL variant,
rs4846922, attenuated the association signal withGALNT2
expression (p > 0.2; Figure S15 and Table S7).Discussion
We identified multiple functional regulatory variants that
contribute to the single strong HDL-C GWAS signal
at GALNT2. Variants rs2281721 and rs4846913, located
2 kb apart, showed strong and consistent allelic and haplo-
type differences in enhancer activity and exhibited tran-
scription-factor binding of USF1 and CEBPB, respectively.
Variants rs2144300 and rs6143660 showed moderate
effects on transcriptional activity and suggestive allelic
differences in binding of nuclear proteins, although we
did not confirm the identity of these potential regulatory
proteins. In addition, rs1555290, in moderate LD (r2 ¼
0.26) with the GWAS variants, also showed suggestive
haplotype differences in enhancer activity and allelic dif-
ferences in binding of a nuclear protein. For all of these var-
iants, the alleles associated with increased HDL-C showed
higher transcriptional activity in reporter assays and wereJournal of Human Genetics 97, 801–815, December 3, 2015 809
Figure 6. CEBPB Binds Differentially to
the Alleles of rs4846913
(A) EMSAs with biotin-labeled probes
containing either the A or C allele of
rs4846913 and incubated with 6 mg
HepG2 nuclear lysate. The arrow indicates
increased protein binding to the A allele
(lanes 2 versus 7). The asterisk indicates ev-
idence of a CEBPB supershift. For competi-
tion reactions, 63-fold excess unlabeled
probe was added.
(B) ChIP experiments were performed in
HepG2 cells (A/C at rs4846913) and Huh-
7 cells (C/C at rs4846913) with CEBPB anti-
body or rabbit IgG control, and a 120-bp
DNA region containing rs4846913 was
amplified via qPCR and quantified with a
standard curve. Results are shown as per-
centages of input DNA. Error bars represent
the SEM of two independent CEBPB and
IgG ChIP experiments each in HepG2
and Huh-7 cells.
(C) CEBPB ChIP-seq reads and DNase-seq
reads from ENCODE data in a region
containing rs4846913 (UCSC Genome
Browser hg19 chromosome coordinates).
Blue indicates reads that contain the A
allele of rs4846913, red indicates reads
that contain the C allele of rs4846913,
and gray indicates reads that do not over-
lap rs4846913 in the peak.associatedwithhigher expression ofGALNT2 in humanhe-
patocyte and human subcutaneous adipose tissue samples.
By testing all variants in strong LD (r2 > 0.7) with lead
HDL-C GWAS variant rs4846914 in luciferase reporter as-
says in both forward and reverse orientations, we identified
the most likely functional regulatory candidates. Although
we used a threshold of r2 > 0.7 to identify the most likely
functional candidates, we cannot rule out the possibility
that we could have missed additional functional variants
in weaker LD with the lead HDL-C-associated variant. Of
14 DNA segments tested, we observed that a segment con-
taining four variants and a separate segment containing
rs2281721 showed up to 49-fold and 75-fold, respectively,
more enhancer activity than did the empty-vector control.
One additional element containing one SNP, rs10864726,
showed more-moderate allelic differences in enhancer ac-
tivity (2.5-fold [T allele] versus 1.8-fold [C allele] more
than the empty vector, p ¼ 0.003) in only the forward
orientation (Figure S16). Compared to a vector control,
the remaining 11 segments did not exhibit enhancer activ-
ity in both orientations, nor did they exhibit significant
differences between alleles. These 11 segments included
one of the lead GWAS SNPs, rs4846914, and the lead SNP
from our fine-mapping analysis, rs17315646. These two
SNPs are located in regions containing H3K4me1,
H3K4me2, H3K4me3, H3K9ac, and H3K27ac peaks in
HepG2 cells and H3K4me1 peaks in adult liver cells,
demonstrating that not all GWAS variants located in regu-
latory elements contribute to regulatory function.
Open-chromatin peaks and histone-modification and
transcription-factor ChIP-seq data in liver cell types810 The American Journal of Human Genetics 97, 801–815, Decembpartially predicted the variants that showed regulatory ac-
tivity. Variants rs4846913, rs2144300, rs1555290, and
rs6143660 overlapped the most peaks (R22 each) of any
candidate variant, but rs2281721 did not overlap any
DNase or FAIRE peaks; instead, it overlapped only four his-
tone-modification peaks (H3K4me1, H3K4me2, H3K9ac,
and H3K27ac) and one transcription-factor ChIP-seq
peak (USF1). We compared our results to the Probabilistic
Identification of Causal SNPs (PICS) algorithm’s44 predic-
tion of candidate causal variants in this region. The vari-
ants that overlapped the most marks of open chromatin
and histone modification in liver cell types (rs4846914,
rs10127775, rs4846913, rs2144300, rs17315646, and
rs10864726) showed the highest prediction scores,
whereas the remaining 19 variants (including rs2281721)
showed a prediction score of 0. Thus, testing many candi-
date variants in experimental assays was necessary for
identifying all variants that showed strong allelic differ-
ences in enhancer activity. We also conclude that testing
all candidate variants in strong LD in combination with
regulatory datasets provides the best chance of identifying
regulatory variants that exhibit allelic differences in
enhancer activity.
One or more of these regulatory variants might also in-
fluence gene expression in other cell types. In addition to
being present in HepG2 cells, rs4846913, rs2144300,
rs1555290, rs6143660, and rs2281721 are also located
within predicted ChromHMM23 strong enhancer chro-
matin states in K562 leukemia cells from ENCODE data12
and ChromHMMactive enhancer chromatin states inmul-
tiple cell types and tissues from Roadmap Epigenomicser 3, 2015
Figure 7. The rs4846914 A Allele Associ-
ated with Increased HDL-C Is Associated
with Higher GALNT2 RNA Expression in
Primary Human Hepatocytes and Subcu-
taneous Adipose Tissue
(A) AEI assays were performed in primary
human hepatocytes from 36 individuals
heterozygous for the intronicHDL-C-associ-
ated lead SNP rs4846914 (p ¼ 5.4 3 107).
rs4846914 was used as a proxy for SNP
rs4846913. DNA results from genomic
DNA are shown as a control, and cDNA
results in this intronic region represent
pre-mRNA.
(B) eQTL queries were performed for the
noncoding GALNT2 variants and GALNT2
expression in subcutaneous adipose tissue
samples from 1,381 individuals from the METSIM study. Circles represent genotyped and imputed DNA variants and the LD r2 values
with lead eQTL variant rs4846922. LD was calculated fromMETSIM genotypes imputed from 1000 Genomes Phase 1 EUR dataset. Chro-
mosomecoordinates correspond toUCSCGenomeBrowserbuildhg19.The lefty axis indicates thelog10(pvalue), the rightyaxis indicates
the recombination rate (cM/Mb), and the x axis indicates position on chromosome 1 (Mb).data,13 including adipose nuclei, CD34 cells, brain,
pancreas, and skeletal muscle (Figure S1).
One or more of the 21 candidate variants that did not
show haplotype or allelic differences in enhancer activity
in both orientations, especially those variants tested indi-
vidually in smaller segments, might also contribute to
the GALNT2 regulatory mechanism. Testing smaller seg-
ments (~100–200 bp) in reporter assays can help with
focusing on individual variants; however, these segments
might fail to capture full regulatory elements. Testing
larger segments can be beneficial because they could
encompass a regulatory element, although segment size
must be balanced with the fact that larger elements might
contain both enhancer and repressor regions and mask
modest allelic effects.
The observation that the 780-bp segment showed similar
haplotype differences in enhancer activity in both a lucif-
erase vector with a minimal promoter and a promoterless
luciferase vector further confirms that rs4846913,
rs2144300, rs1555290, and rs6143660 are located within
a regulatory element that drives expression. We did not
find annotated evidence of an alternative promoter or alter-
native splicing in this region; however, we cannot rule out
alternate mechanisms. Using qRT-PCR and strand-specific
primers, we detected hepatocyte and HepG2 RNA tran-
scribed from both strands within GALNT2 intron 1 (T.R.,
unpublished data). This result is not unexpected, given
that transcription initiation has been found to occur in
both directions at both promoters and enhancers.45
The functional regulatory variants at this locus might
bind multiple transcription factors and act together in a
complex to influence transcriptional enhancer activity.
Increased binding of CEBPB to the rs4846913 A allele, asso-
ciated with increased HDL-C, is consistent with the fact
that CEBPB acts as a transcriptional activator.46 CEBPB is
a CCAAT/enhancer binding transcription factor that plays
diverse roles in cell proliferation, development, adipocyte
differentiation, immune response, and liver gene expres-
sion.47–51 Knockdown of CEBPB (71% of negative control)The Americanby siRNA in HepG2 cells resulted in a modest 22% decrease
in GALNT2 expression (p ¼ 0.058; Figure S17), suggesting
that other transcription factors within a complex might
bind to rs4846913 and be sufficient to preserve substantial
enhancer activity and GALNT2 expression in HepG2 cells.
Nonetheless, our data suggest that differential binding of
CEBPB to rs4846913 is one potential molecular mecha-
nism underlying the HDL-C association.
The other candidate regulatory variants, rs2281721,
rs2144300, rs1555290, and rs6143660, might also bind
one or more transcription factors. Binding of USF1 to
rs2281721 was allele specific in EMSAs; however, ChIP
assays in HepG2 (C/T at rs2281721) and Huh-7 (C/C at
rs2281721) cells suggest that USF1 binds to both alleles
of rs2281721 in a native chromatin context. Therefore,
USF1 might not drive the allelic differences observed in
EMSAs and in HepG2 and Huh-7 cell transcriptional re-
porter assays. USF1 is an upstream stimulatory factor and
has been shown to bind to lipid- and glucose-meta-
bolism-related genes52–54 and affect cholesterol home-
ostasis, insulin sensitivity, and body-fat mass.55 The other
three potential regulatory variants, rs2144300, rs1555290,
and rs6143660, each overlap R13 transcription-factor
ChIP-seq peaks in HepG2 cells. Future experiments will
be valuable for confirming the role of CEBPB and USF1
in GALNT2 expression, identifying other transcription fac-
tors contributing to the haplotype differences in transcrip-
tional enhancer activity, detecting physical interactions of
this enhancer region, and fully characterizing this com-
plex molecular mechanism at GALNT2.
The transcriptional reporter assays all exhibit the same
direction of effect; alleles associated with increased HDL-
C are also associated with increased enhancer activity. In
the assay of liver AEI (Figure 7A) and the study on adipose
eQTLs (Figure 7B and Figure S15), the rs4846914 A allele
associated with increased HDL-C was associated with
higher GALNT2 expression. Although the HDL-C GWAS
variants were not associated with GALNT2 expression
in an eQTL dataset of more than 400 liver samplesJournal of Human Genetics 97, 801–815, December 3, 2015 811
(p < 3.95 3 108)56 or in our eQTL analysis of primary
hepatocyte samples from 50 individuals (Figure S14),
significant associations were previously observed57 in
146 human liver biopsy samples (p ¼ 0.002) and 105 ca-
rotid-atherosclerotic-plaque biopsy samples (p ¼ 0.001),
consistent with our observed direction of effect. The evi-
dence of variant association with the level of GALNT2
expression in both liver and adipose tissue is consistent
with the frequent observation that eQTLs are shared
across multiple tissues.58 This direction of effect is oppo-
site to the effect on HDL-C of a previous study that
used adeno-associated viral vectors to overexpress and
knock down mouse Galnt22 and a study that observed a
rare GALNT2 missense variant in humans.21 Notably,
our observed direction of effect of the human GWAS var-
iants is consistent with recent unpublished studies
demonstrating that total loss of function of GALNT2 in
humans, mice, rats, and cynomolgus monkeys consis-
tently results in lower HDL-C (S. Khetarpal, D. Rader,
personal communication). GALNT2 remains a likely
candidate gene, considering the association between the
GWAS variants and GALNT2 expression, but not expres-
sion of 16 other potential target genes within 1 Mb in
samples of subcutaneous adipose tissue. However, the reg-
ulatory variants we identified might also act to increase
expression of other nearby genes that might contribute
to the HDL-C association signal. Identification of the
functional variants responsible for the human GWAS
signal can provide further understanding of the direction
of effect in humans and lead to a greater insight into the
molecular mechanisms of how these variants might influ-
ence gene expression and function.
In the METSIM cohort, the studied variants were most
strongly associated with traits correlated with total choles-
terol in medium HDL, including cholesterol esters in me-
dium HDL (r2 ¼ 1.0), concentrations of medium HDL par-
ticles (>0.9), phospholipids in medium HDL (>0.9), and
free cholesterol in medium HDL (>0.9). Sub-phenotype as-
sociations can provide additional insight into the function
of GWAS loci.59 GALNT2 might act during specific steps of
HDL-particle formation or remodeling by directly glycosy-
lating lipid modifiers or enzymes, such as ANGPTL320 or
LIPG, an enzyme that has been shown to hydrolyze phos-
pholipids in HDL60,61 and remodel HDL particles.62 More
work is necessary for determining the mechanism(s) by
which GALNT2 might influence the size of HDL particles.
Overall, this study demonstrates multiple lines of evi-
dence suggesting that at least two regulatory variants
might act to regulate expression of GALNT2, a gene
involved in HDL-C metabolism (Figure S18). The eQTL
and AEI data clarify the direction of effect by which the
GWAS variants act. Our study joins a growing set of studies
that implicate multiple functional regulatory variants at a
GWAS locus,63,64 highlighting the complexity of molecu-
lar mechanisms underlying GWAS loci, and emphasizes
that multiple common functional regulatory variants
might work in concert.812 The American Journal of Human Genetics 97, 801–815, DecembSupplemental Data
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